{"name": "Diabetes type2","source": "2018 Clinical Practice Guidelines. Quick Reference Guide. Diabetes Canada.","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"name": "assess risk factors","description": "-  Family history (first-degree relative with type 2 diabetes)\r\n\t-  High risk populations (non-white, low socioeconomic status)\r\n\t-  History of GDM\/prediabetes\r\n\t-  Cardiovascular risk factors\r\n\t-  Presence of end organ damage associated with diabetes\r\n\t-  Other conditions and medications associated with diabetes (see CPG Chapter 4, Screening for Diabetes in Adults, Table 1)\r\n\t\r\n\tAge >= 40 years or high risk* (33% chance of developing type 2 diabetes within 10 years).\r\n\tor very high risk (50% chance of developing type 2 diabetes within 10 years).\r\n\t\r\n\t*using a validated risk calculator (e.g. CANRISK)","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"name": "screen using FPG and/or A1C","description": "If asymptomatic and A1C or FPG are in the diabetes range, repeat the same test (A1C or FPG) as a confirmatory test. \r\nIf both FPG and A1C are available and only one is in the diabetes range, repeat the test in the diabetes range as the confirmatory test. \r\nIf both A1C and FPG are available and are each in the diabetes range, diabetes is confirmed.\r\nIf symptoms of overt hyperglycemia are present, diagnosis of diabetes can bedetermined with one test (A1C, FPG, 2hPG, random PG) in the diabetes range, see Chapter 3, CPG.","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "age >= 40 or (very) high risk","children": [{"name": "diabetes type2 treatment","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "FPG >= 7 OR A1C >= 6.5","children": [{"name": "health behavior interventions","description": "Start healthy behaviour interventions (nutritional therapy, weight management, physical activity) +\/- metformin","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState"},{"name": "blood glucose lowering therapy","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState"},{"name": "CVD protection","description": "Does the patient have cardiovascular disease?\r\n- Cardiac ischemia (silent or overt)\r\n- Peripheral arterial disease\r\n- Cerebrovascular\/carotid disease","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"name": "Statin and ACEi/ARB and ASA","description": "Statin(1) + ACEi\/ARB(2) + ASA(3)\r\n(1) Dose adjustments or additional lipid therapy warranted if lipid target (LDL-C <2.0 mmol\/L) not being met. \r\n(2) ACE-inhibitor or ARB (angiotensin receptor blocker) should be given at doses that have demonstrated vascular protection (eg. perindopril 8 mg once daily [EUROPA trial], ramipril 10 mg once daily [HOPE trial], telmisartan 80 mg once daily [ONTARGET trial]). \r\n(3) ASA should not routinely be used for the primary prevention of cardiovascular disease in people with diabetes. ASA may be used for secondary prevention. Consider clopidogrel if ASA-intolerant","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "has CVD","children": [{"name": "check glycemic target","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","children": [{"name": "Liraglutide, Empagliflozin or Canagliflozin","description": "Liraglutide, Empagliflozin or Canagliflozin(4)\r\n\t(4) Canagliflozin: avoid in people with prior lower extremity amputation.","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "not at glycemic target"}]}]},{"name": "check age","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "has no CVD","children": [{"name": "check risk factors","description": "- age >= 40?\r\n- age >= 30 and diabetes >15 years?\r\n- warranted for statin therapy based on the Canadian Cardiovascular Society Lipid Guidelines?","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "age >= 30","children": [{"name": "Statin","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "applicable risk factors"}]},{"name": "check MVD and risk factors","description": "Does the patient have microvascular disease?\r\n- Retinopathy\r\n- Kidney disease (ACR >= 2.0)\r\n- Neuropathy\r\n\r\nIs the patient:\r\n- age >= 55 with additional CV risk factors?","node_type": "decision_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "age >= 55","children": [{"name": "Statin and ACEi/ARB","node_type": "task_node","workflow_state": "inactiveState","decisional_state": "chosenState","condition": "MVD or risk factors"}]}]}]}]}]}]}]}